Funding will support a randomized Phase 2B study of the novel sonodynamic therapy in patients with newly diagnosed glioblastoma.
Filter news by year
- All (7)
- 2025
- 2024
- 2023
- 2022
- 2021
“SDT’s ability to selectively induce immediate tumor cell death while sparing healthy brain tissue is unprecedented.”
The results from their first-in-human study demonstrated that median overall survival was doubled and progression-free survival improved 3-fold. The Company’s novel sonodynamic therapy platform selectively targets and destroys cancer cells in the brain while preserving healthy tissue.
Milestone arrives as the company closes a $14 million follow-on Series A financing round to expand the clinical program for high-grade gliomas, including glioblastomas, and pursue additional indications.
The company is currently enrolling patients in a multi-center Phase 1 clinical trial for the treatment of recurrent glioblastoma (GBM)
SAB to provide meaningful guidance as the company begins a first-in-human (FIH) clinical trial of their proprietary, non-invasive sonodynamic drug-device therapy system for recurrent high-grade gliomas
Funds to support first-in-human (FIH) clinical trial of the company’s proprietary, non-invasive sonodynamic drug-device therapy system for recurrent high-grade gliomas